Grand Rounds

Friday, January 5, 9:00am

Endocrine Adverse Events with Cancer Therapies

featuring

Kevan Herold, MD
C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology)

55 Park Street Auditorium | Zoom Access
Continental breakfast will be available

Needs: Endocrine adverse events are common with cancer therapies, particularly checkpoint inhibitors. There are no known treatments to prevent these events and it is not known who is likely to develop them. Identifying those at risk and the mechanisms of disease may reduce morbidity from these conditions.

Objectives: Identify the types and frequencies of endocrine AEs following cancer therapies. Understand potential mechanisms of their development. Understand personal features that identify those at risk for these AEs.

Dr. Herold is an endocrinologist with a background in translational immunology and understanding the basis for autoimmune diseases and developing new therapies based on the understanding of disease mechanisms. He received his medical degree from Jefferson Medical College and his area of focus has largely been in the field of autoimmune Type 1 diabetes.

Dr. Herold’s lab also is interested in autoimmune diseases that occur in patients with cancers who are treated with new immune therapies such as checkpoint inhibitors. They are studying the mechanisms that lead to these adverse events with the objective to prevent them from occurring.